PMID- 23397155
OWN - NLM
STAT- MEDLINE
DCOM- 20140424
LR  - 20211021
IS  - 1699-3055 (Electronic)
IS  - 1699-048X (Print)
IS  - 1699-048X (Linking)
VI  - 15
IP  - 10
DP  - 2013 Oct
TI  - Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast 
      cancer: biomarkers and pathologic response.
PG  - 810-7
LID - 10.1007/s12094-013-1006-4 [doi]
AB  - PURPOSE: The primary aim of this trial was to assess the rate of pathologic 
      complete responses (pCR) of doxorubicin/cyclophosphamide (AC) followed by 
      bevacizumab/docetaxel (BT), as neoadjuvant therapy for breast cancer (BC). 
      Furthermore, the association between biomarkers and the pCR was explored. 
      METHODS: Patients with HER-negative operable stage II-III BC >/= 2 cm were 
      enrolled. Four cycles of AC (A 60 mg/m(2) and C 600 mg/m(2), every 3 weeks) 
      followed by 4 cycles of BT (B 15 mg/kg and T 75 mg/m(2), every 3 weeks), were 
      planned. A core-biopsy was performed for biological markers assessment. RESULTS: 
      Seventy-two women were included. Forty-three (63 %) patients were hormone 
      receptor-positive. Sixty-four (89 %) completed the planned treatment, and 66 
      evaluable patients underwent surgery (92 %): a pCR was achieved in 16 of them 
      (24, 95 % CI 15-36 %). pCR was significantly higher in tumors hormone 
      receptor-negative, and in those with Angiotensin II type 1 receptor (AGTR1) 
      protein overexpression. The overall clinical response rate was 86 % (95 % CI 
      76-93 %), including 42 complete responses. No unexpected toxicities or 
      treatment-related deaths were observed. CONCLUSION: This regimen showed a 
      remarkable clinical and pathological activity: the suggested relation between pCR 
      and AGTR1 overexpression should be confirmed in larger trials.
FAU - Sanchez-Rovira, P
AU  - Sanchez-Rovira P
AD  - Servicio de Oncologia Medica, Complejo Hospitalario de Jaen, Avda. del Ejercito 
      Espanol, 10, 23007, Jaen, Spain, oncopsr@yahoo.es.
FAU - Segui, M A
AU  - Segui MA
FAU - Llombart, A
AU  - Llombart A
FAU - Aranda, E
AU  - Aranda E
FAU - Anton, A
AU  - Anton A
FAU - Sanchez, A
AU  - Sanchez A
FAU - Lomas, M
AU  - Lomas M
FAU - Jaen, A
AU  - Jaen A
FAU - Fernandez, M
AU  - Fernandez M
FAU - Porras, I
AU  - Porras I
FAU - Dalmau, E
AU  - Dalmau E
FAU - Morales, S
AU  - Morales S
FAU - de la Haba-Rodriguez, J
AU  - de la Haba-Rodriguez J
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20130209
PL  - Italy
TA  - Clin Transl Oncol
JT  - Clinical & translational oncology : official publication of the Federation of 
      Spanish Oncology Societies and of the National Cancer Institute of Mexico
JID - 101247119
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - 0 (Taxoids)
RN  - 15H5577CQD (Docetaxel)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bevacizumab
MH  - Biomarkers, Tumor/metabolism
MH  - Breast Neoplasms/*drug therapy/metabolism/pathology
MH  - Carcinoma, Ductal, Breast/*drug therapy/metabolism/secondary
MH  - Carcinoma, Lobular/*drug therapy/metabolism/secondary
MH  - Cyclophosphamide/administration & dosage
MH  - Docetaxel
MH  - Doxorubicin/administration & dosage
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lymphatic Metastasis
MH  - Middle Aged
MH  - Neoadjuvant Therapy
MH  - Neoplasm Staging
MH  - Preoperative Care
MH  - Prognosis
MH  - Receptor, ErbB-2/*metabolism
MH  - Receptors, Estrogen/metabolism
MH  - Receptors, Progesterone/metabolism
MH  - Remission Induction
MH  - Taxoids/administration & dosage
PMC - PMC3776259
EDAT- 2013/02/12 06:00
MHDA- 2014/04/25 06:00
PMCR- 2013/02/09
CRDT- 2013/02/12 06:00
PHST- 2012/11/15 00:00 [received]
PHST- 2013/01/13 00:00 [accepted]
PHST- 2013/02/12 06:00 [entrez]
PHST- 2013/02/12 06:00 [pubmed]
PHST- 2014/04/25 06:00 [medline]
PHST- 2013/02/09 00:00 [pmc-release]
AID - 1006 [pii]
AID - 10.1007/s12094-013-1006-4 [doi]
PST - ppublish
SO  - Clin Transl Oncol. 2013 Oct;15(10):810-7. doi: 10.1007/s12094-013-1006-4. Epub 
      2013 Feb 9.